Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC

  • STATUS
    Recruiting
  • End date
    Dec 23, 2022
  • participants needed
    310
  • sponsor
    Sun Yat-sen University
Updated on 23 January 2021
tyrosine
measurable disease
kinase inhibitor
neutrophil count
EGFR
cancer chemotherapy
targeted therapy
gefitinib
advanced lung cancer
recurrent non-small cell lung cancer
lung carcinoma

Summary

Gefitinib is currently the standard-of-care for patients with activating-EGFR mutant advanced non-small cell lung cancer (NSCLC). However, ~30-40% patients are still nonresponsive, and experience significantly varying duration of response and survival rate. Anlotinib is an efficient multi-target tyrosine kinase inhibitor (TKI) that effectively block the migration and proliferation of endothelial cells and reduce tumor microvascular density by targeting VEGFRs, FGFRs, PDGFRs. It has been proved to be safe and effective in advanced lung cancer after second-line standard chemotherapy failure, which can significantly extend the survival of patients and approves as a third-line treatment for advanced NSCLC. Here, we prepared to evaluate whether the combination of gefitinb and anlotinib can preferably improved survival of untreated NSCLC with EGFR activating mutation.

Details
Condition Non-Small Cell Lung Cancer
Treatment Placebo, Gefitinib, Anlotinib Hydrochloride
Clinical Study IdentifierNCT04028778
SponsorSun Yat-sen University
Last Modified on23 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

\. 18 and 75 years of age
Eastern Cooperative Oncology Group(ECOG)performance scale 0 - 1
Life expectancy of more than 3 weeks
Histologically confirmedlocally advanced and/or metastatic non-squamous NSCLC of stage IIIB (unsuitable for radiotherapy) or IV or recurrent NSCLC with measurable lesion/ according to RECIST 1.1 which has not received radiotherapy or cryotherapy
Documented evidence of tumor harboring an activating EGFR mutation (exon19 del and L858R)
None previous chemotherapy or targeted therapy. NOTE: neoadjuvant and/or adjuvant therapy is allowed which is completed before 6 months
Prior radiation therapy is allowed if: 25% or less of total bone marrow had been irradiated,pelvis and chest had not been irradiated; at least 4 weeks have elapsed from the completion of radiation treatment, and the acute toxicity from radiation treatment had been recover; irradiated lesion is not including measurable lesions unless documented progress after radiation
Adequate hepatic, renal, heart, and hematologic functions (Absolute Neutrophil Count(ANC) 1.5109/L, Platelet (PLT) 100109/L, Hemoglobin(HB) 100 g/L, total bilirubin within 1.5the upper limit of normal(ULN), and serum transaminase2.5the Upper Limit Of Normal(ULN), serum creatine 1 x Upper Limit Of Normal(ULN), creatinine clearance rate 50ml/min
For women of child-bearing age, the pregnancy test results (serum or urine) within 7 days before enrolment must be negative. They will take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. For men (previous surgical sterilization accepted), will take appropriate methods for contraception during the study until the 8th week post the last administration of study drug
Signed and dated informed consent. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure

Exclusion Criteria

small cell lung cancer (including small cell and non-small cell mixed lung cancer)
Symptomatic brain metastases (Patients who have no symptoms and is not needed to receive therapy before 21 days may participate in this trial, but need to be confirmed by MRI\CT or venography that no hematencephalon symptom)
Radiologically documented evidence of tumor lesions from large vessels 5mm or major blood vessel invasion or encasement by cancer; Obvious cavity or necrosis formed in the tumor
\. hypertensive patients are in the combination therapy of two or more antihypertensive drugs
patients with positive T790M mutation by Gene detection
Patients who suffered from grade II or above myocardial ischemia or myocardial infarction, uncontrolled arrhythmias (including QT interval male 450 ms, female 470 ms). Grade III-IV cardiac insufficiency according to New York Heart Association(NYHA) criteria or echocardiography check: left ventricular ejection fraction (LVEF)<50%
History of pulmonary interstitial diseases or concurrent pulmonary interstitial diseases
Coagulation disfunctionINR>1.5 or PT>Upper Limit Of Normal(ULN)+4s or Activated Partial Thromboplastin Time (APTT) >1.5 Upper Limit Of Normal(ULN), hemorrhagic tendency or receiving the therapy of thrombolysis or anticoagulation
Daily hemoptysis up to two teaspoons or more before enrollment
History of clinically relevant major bleeding event=<3 months (e.g. gastrointestinal hemorrhage, Hemorrhagic acne bleeding gastric ulcer, occult blood test (++), and vasculitis
Within 12 months before the first treatment occurs artery / venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack(TIA), hematencephalon, cerebral infarction), deep vein thrombosis and pulmonary embolism, etc
Known inherited and acquired hemorrhagic and thromboplastic possibility (such as hemophilia, coagulopathy, thrombocytopenia, hypersplenism, etc.)
Long-term untreated wounds or fracturesin addition to tumor-induced pathological fractures
Within 4 weeks of major surgery and/or injures, fractures , ulceration
Significant factors that influence the ingestion and absorption of medicine, (e.g. unable swallow, chronic diarrhea and intestinal obstruction)
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess 6 months
Urine protein++, and 24h urine protein quantitation1.0g
Symptomatic serous effusion requiring treatment .(including hydrothorax, ascites, hydropericardium)
Active infection need antimicrobial treatmentssuch as antibiotics and antiviral drugs should be used, excluding anti-hepatitis B treatment and antifungal therapy
History of psychiatric drugs abuse and not be abstinent, or dysphrenia
Less than 4 weeks from the last clinical trial
History or concomitant other malignancy except cured basal cell skin cancer, or carcinoma in situ of the cervix, or superficial bladder cancer
Administration of strong/potent cytochrome P450 (CYP)3A4 inhibitors within 7 days, or inducers within 12 days
Pregnant or breastfeeding womenpatients who have fertility are unwilling or unable to take effective contraceptive measures
Other conditions regimented at investigators' discretion
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note